Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash flows from operating activities:
Net loss	$ (25,796)	$ (4,443)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	627	616
Non-cash interest expense	13	0
Changes in operating assets and liabilities:
Income tax receivable	(33)	(251)
Prepaid expenses and other current assets	(219)	130
Deposits held for clinical trial costs	(2,561)	0
Accounts payable	2,483	484
Accrued liabilities	(931)	(194)
Net cash used in operating activities	(8,680)	(3,658)
Cash flows from investing activities:
Net cash used in investing activities	(655)	0
Cash flows from financing activities:
Proceeds from exercise of stock purchase warrants	0	1,042
Net cash provided by financing activities	0	1,042
Effect of exchange rate changes on cash	(2)	(1)
Net change in cash	(9,337)	(2,617)
Cash and cash equivalents at beginning of period	11,867	9,022
Cash and cash equivalents at end of period	2,530	6,405
Supplemental disclosure of cash flow information:
Cash paid during period for interest	7	7
CPP [Member]
Adjustments to reconcile net loss to net cash used in operating activities:
Write off of in process research and development (IPR&D)	17,737	0
Cash flows from investing activities:
Investment in IPR&D	(659)	0
Cash aquired in merger	4	0
Supplemental Disclosure of non-cash transactions:
Fair value of common stock, stock options and stock warrants issued as consideration for asset acquisition	$ 9,605	$ 0